Tiefenbacher Group draws attention to blood donation

Tiefenbacher Group draws attention to blood donation

On today's World Blood Donor Day, Tiefenbacher Group would like to actively support the Red Cross blood donation services and draw attention to blood donation and its importance for society with the #MissingType campaign.

Anyone can suddenly find themselves in need of a blood transfusion. Some accident victims are dependent on 50 or more units of blood to survive. Many medical interventions – such as operations or cancer treatments – are only possible today if a sufficient amount of human blood is available. In Germany alone, around 15,000 blood donations and approx. 5,000 plasma donations are needed every day.

It has not yet been possible to replace blood with another liquid or substance. Blood is therefore unique and blood donations are absolutely essential for patient care. Patients are therefore dependent on the constant commitment of blood donors.

We are delighted about the many employees who have volunteered to donate their blood and thus give other people the opportunity to continue living. Thank you for your support!

About Tiefenbacher Group – Pioneering Healthcare since 1963

Tiefenbacher Group is a purpose-driven and 100% family-owned healthcare company providing best-in-class solutions along the entire pharmaceutical value chain. From the initial idea to market access of high-quality medicines around the world: We distribute APIs and develop, produce, and register finished dosage forms (FDF) including highly potent drugs as well as medical devices and e-health-solutions. Our purpose is to improve people’s lives by making pharmaceuticals more affordable, more available, and better than ever before.

For further information about our solutions for better healthcare and our in-house capabilities to develop and commercialize pharmaceutical products (including highly potent drugs) and e-health-solutions for global markets, please contact us by email at info@tiefenbacher.com or visit us on www.tiefenbachergroup.com

TIEFENBACHER PHARMACEUTICALS, a part of Tiefenbacher Group, develops and commercializes genericvalue added, and innovative pharmaceuticals as well as medical devices and e-health solutions worldwide. We provide over 180+ pharmaceutical products across various therapeutic categories in 10+ dosage forms. With our in-house product development and manufacturing, we can address specific therapeutic needs in unique formulations of prescription drugs (Rx) and over-the-counter (OTC) medicines for global markets (including highly potent drugs).
For more information about our finished dosage (FDF) forms and healthcare solutions, please contact Tiefenbacher Pharmaceuticals: info@tiefenbacher.com or visit us on: www.tiefenbacher-pharmaceuticals.com


Tiefenbacher Group Buprenorphin launch Australia

Tiefenbacher New Market Launch: Buprenorphine in Australia

Tiefenbacher Pharmaceuticals successfully prepared the launch of the analgesic Buprenorphine as Transdermal Patch in Australia.

We at Tiefenbacher Pharmaceuticals strongly believe that our high-quality medicines should be affordable and available for all patients around the world. A key point here is that this applies to everyone, regardless of their nationality or income. That´s why we are thrilled to share that we have successfully prepared the launch of the generic version of the analgesic Buprenorphine as Transdermal Patch in Australia.

Affordable Medicines (fka Generics) are therapeutically equivalent to their branded counterparts with a lower price due to losing patent protection. The low cost of generic medications promotes patient affordability and contributes to lower per capita healthcare spending.

Buprenorphine belongs to a class of drugs known as opioid analgesics. Buprenorphine patches are used to help relieve severe and persistent pain (such as due to arthritis or chronic back pain). Our cooperation partner marketed the Transdermal Patches in the strengths 5mcg, 10mcg, 15mcg, and 20mcg. This product has already been launched in several international markets before.

The successful launch of this affordable medicine is a testament to the hard work and dedication of our team. The positive impact for the Australian healthcare system is one thing we are particularly excited about. We look already forward to further market entries of our high-quality medicines.

Please click the highligthed words if you would like to know more about our product portfolio.

TIEFENBACHER PHARMACEUTICALS  is a part of Tiefenbacher Group. We develop and commercialize generic, value added, and innovative pharmaceuticals as well as medical devices and e-health-solutions worldwide. We provide over 180+ pharmaceutical products across various therapeutic categories in 10+ dosage forms. With our in-house product development and manufacturing, we can address specific therapeutic needs in unique formulations of prescription drugs (Rx) and over-the-counter (OTC) medicines for global markets.  

For more information about our finished dosage forms (FDF) including highly potent drugs and e-healthcare solutions, please contact us at  info@tiefenbacher.com or visit us on  www.tiefenbacher-pharmaceuticals.com

Tiefenbacher Group Buprenorphin launch Australia

NEW MARKET LAUNCH: Bilastine as Oral Dispersible Tablet (ODT)

Tiefenbacher Pharmaceuticals successfully prepared the launch of the antihistamine Bilastine as Oral Dispersible Tablet (ODT) medicine in Germany

The allergy season is undoubtedly in full swing. We at Tiefenbacher Group are therefore thrilled to announce that we have successfully prepared the launch of our latest anti-allergy medicine, Bilastine Oral Dispersible Tablet (ODT) in Germany – available from now on in German pharmacies without a prescription. We are particularly pleased to offer Bilastine (ODT) for the first time in 10mg strawberry flavoured tablets which we developed especially for children aged 6-11 years.

Patients who suffer from the following allergic symptoms: Hay fever, hives, urticaria and other allergic reactions are thus offered a more convenient and user-friendly way to control their allergy. The introduction of the oral dispersible tablet form is basically a response to the needs of patients – especially to those who are seeking a more flexible and also a discreet way to manage their allergies, particularly when on the go.

Bilastine Oral Dispersible Tablet (ODT) is designed to disintegrate quickly in the mouth without the need for water. This way, patients with difficulties swallowing tablets or without immediate access to water can use the device with ease.

The 10 mg tablets for children and the 20 mg tablets for adults have been developed in Tiefenbacher Group´s own laboratories. They will be marketed by our partner, a well-known international pharmaceutical company. With the market entry of Bilastine Oral Dispersible Tablet we enable patients in Germany a better access to an important medicine since, it is currently available in pharmacies without a prescription needed.

The successful launch of this antihistamine reflects our ongoing commitment to providing patients with high-quality, cost-effective medications. Undeniably it is a testament to the hard work and dedication of the team.

Finally, we are particularly excited about the positive impact this achievement will have. However we look forward to further market entries with high-quality medicines – with a patient-centred approach for better healthcare.

TIEFENBACHER PHARMACEUTICALS  is a part of Tiefenbacher Group. We develop and commercialize generic, value added, and innovative pharmaceuticals as well as medical devices and e-health-solutions worldwide. We provide over 180+ pharmaceutical products across various therapeutic categories in 10+ dosage forms. With our in-house product development and manufacturing, we can address specific therapeutic needs in unique formulations of prescription drugs (Rx) and over-the-counter (OTC) medicines for global markets.  

For more information about our finished dosage forms (FDF) including highly potent drugs and e-healthcare solutions, please contact us at  info@tiefenbacher.com or visit us on  www.tiefenbacher-pharmaceuticals.com


Featured Video Play Icon

Tiefenbacher Group celebrates The International Day of Families

Today we celebrate The International Day of Families!

We would like to use the International Day of Families to talk about our Tiefenbacher Group family. Since 1963 Tiefenbacher Group is a 100% family-owned healthcare company. Until today the company is owned by the direct descendants of our founding father Alfred E. Tiefenbacher. To this day, his unique entrepreneurial spirit is our driving force in pioneering healthcare by making medicines more affordable, more globally available, and better than before.

The greatest strength of Tiefenbacher Group is our employees, our family. We believe that their curiosity, their passion for healthcare, and their diversity are the foundation of our success.

Our employees´ performance achievements and their inventiveness are the daily basis for our entrepreneurial accomplishments to make a sustainable difference in patient care.

We put our passion for improving people’s lives into practice. Therefore we want every employee to enjoy coming to work every day. Working at Tiefenbacher Group is characterized by mutual appreciation, fairness, and transparency. In our day-to-day work we certainly focus on challenging the status quo. Furthermore we are highly optimistic, take initiative, and strive for speed and pragmatism making things happen. A career with us means working for a company that values you and your well-being.

Therefore, we endeavor to provide every member of our Tiefenbacher Group family with the working environment they need to thrive – because we believe that those who are passionate about what they do are the ones who succeed.

Happy International Day of Families!

Tiefenbacher Group is a purpose-driven and 100% family-owned healthcare company providing best-in-class solutions along the entire pharmaceutical value chain. From the initial idea to market access of high-quality medicines around the world: We distribute APIs and develop, produce, and register finished dosage forms (FDFs) including highly potent drugs as well as medical devices. Our purpose is to improve people’s lives by making pharmaceuticals more affordable, more available, and better than ever before.

For further information about TIEFENBACHER GROUP and our solutions for better healthcare and our in-house capabilities to develop and commercialize pharmaceutical products for global markets (including highly potent drugs) please contact us by email at info@tiefenbacher.com or visit us on:  www.tiefenbachergroup.com

Tiefenbacher Pharmaceuticals, a part of Tiefenbacher Group, develops and commercializes generic, value added, and innovative pharmaceuticals as well as medical devices worldwide. We provide over 180+ pharmaceutical products across various therapeutic categories in 10+ dosage forms. With our in-house product development and manufacturing, we can address specific therapeutic needs in unique formulations of prescription drugs (Rx) and over-the-counter (OTC) medicines for global markets (including highly potent drugs).

For more information about our finished dosage forms and healthcare solutions, please contact Tiefenbacher Pharmaceuticals: info@tiefenbacher.com or visit us on: www.tiefenbacher-pharmaceuticals.com


Featured Video Play Icon

TIEFENBACHER API + INGREDIENTS offers custom synthesis of intermediates & APIs

Synthesis of Active Pharmaceutical Ingredients (API) : From route scouting to lab scale development to commercial supply 

Did you know that Tiefenbacher API + Ingredients not only offers a broad range of high-quality APIs, but also offers custom synthesis of intermediates & APIs? 

The synthesis of APIs is a critical step in the development and manufacturing of high-quality pharmaceuticals. It is a multi-step process involving numerous chemical transformations. Particularly purification, separation and operations on a range of raw materials with different physical and chemical properties. 

We at TIEFENBACHER API + INGREDIENTS surely make it right the first time, from grams to tons. Generally a structured and methodical approach enables us to identify your individual requirements and implement them precisely. Our significantly strong network of 200+ manufacturing partners and our sophisticated market intelligence allow us to choose the best fit. We work closely with you and the selected CDMO during all the planning and execution phases. Thus, to assure we meet your and the product’s requirements. 

Whatever challenges you face throughout the sourcing process or the synthesis of APIs for your pharmaceuticals. Regardless of the size or complexity of your project, you can be sure that together we can develop a customised solution for your specific requirements.

TIEFENBACHER API + INGREDIENTS, a part of TIEFENBACHER GROUP, is a pharmaceutical full-service distributor for high-quality APIs and controlled substances with value-added services. We offer more than 600+ APIs (Human + Veterinary) in all fourteen ATC-Groups for safe, reliable pharmaceuticals.
For more information around our raw materials with best value seal (Better Access – Better Quality – Better Quality), please contact TIEFENBACHER API + INGREDIENTS: info-api@tiefenbacher.com or visit us on: www.tiefenbacher-api.com

Tiefenbacher Pharmaceuticals, a part of Tiefenbacher Group, develops and commercializes generic, value added, and innovative pharmaceuticals as well as medical devices worldwide. We provide over 180+ pharmaceutical products across various therapeutic categories in 10+ dosage forms. With our in-house product development and manufacturing, we can address specific therapeutic needs in unique formulations of prescription drugs (Rx) and over-the-counter (OTC) medicines for global markets (including highly potent drugs).

For more information about our finished dosage forms and healthcare solutions, please contact Tiefenbacher Pharmaceuticals: info@tiefenbacher.com or visit us on: www.tiefenbacher-pharmaceuticals.com


Tiefenbacher Group renovation of headquarters in Hamburg

Tiefenbacher Group renovation of headquarters in Hamburg

Tiefenbacher Group is keeping you updated on the ongoing renovation of our headquarters at the Port of Hamburg in Germany.

This month we reopened our 3rd floor and we are happy to present you some of the results of the remodeling.

Our office is becoming a state-of-the-art and innovative workspace that reflects our culture of entrepreneurship, professionalism, and openness. The open-plan concept encourages creativity, collaboration, and teamwork among our employees. Overall, the interior is airy, transparent, and flooded with light.

The modernization also allowed us to integrate new decorative elements into the workspace. By this we also take the chance to represent the connection to our location in India. When installing the Tuk-tuk, some of our colleagues had to lend a hand and drag the vehicle up the stairs to the upper floor. This involved a lot of sweating and swearing. In the end, it was successfully put in its place and now stands there looking very inviting.

We are convinced that the new premises directly on the banks of the Elbe offer a great working environment. Which also promotes the growth and well-being of our employees. As hybrid working and working from home have become the new normal for many people. Tiefenbacher is keen to keep its workspace at the cutting edge.

Finally we would like to thank all the helpers once again. Naturally we are looking forward to showing you more pictures as soon as the final 4th floor is completed. The full modernization of our headquarters is expected to be completed later this year. We will keep you updated on the progress and look forward to welcoming you to our new offices soon!

Tiefenbacher Group renovation of headquarters in Hamburg

TIEFENBACHER PHARMACEUTICALS, a part of Tiefenbacher Group, develops and commercializes genericvalue added, and innovative pharmaceuticals as well as medical devices and e-health solutions worldwide. We provide over 180+ pharmaceutical products across various therapeutic categories in 10+ dosage forms. With our in-house product development and manufacturing, we can address specific therapeutic needs in unique formulations of prescription drugs (Rx) and over-the-counter (OTC) medicines for global markets (including highly potent drugs).
For more information about our finished dosage (FDF) forms and healthcare solutions, please contact Tiefenbacher Pharmaceuticals: info@tiefenbacher.com or visit us on: www.tiefenbacher-pharmaceuticals.com

About Tiefenbacher Group – Pioneering Healthcare since 1963

Tiefenbacher Group is a purpose-driven and 100% family-owned healthcare company providing best-in-class solutions along the entire pharmaceutical value chain. From the initial idea to market access of high-quality medicines around the world: We distribute APIs and develop, produce, and register finished dosage forms (FDF) including highly potent drugs as well as medical devices and e-health-solutions. Our purpose is to improve people’s lives by making pharmaceuticals more affordable, more available, and better than ever before.

For further information about our solutions for better healthcare and our in-house capabilities to develop and commercialize pharmaceutical products (including highly potent drugs) and e-health-solutions for global markets, please contact us by email at info@tiefenbacher.com or visit us on www.tiefenbachergroup.com


Tiefenbacher Group invites young people to Girls’ & Boys’ Day

Tiefenbacher Group invites young people to Girls’ & Boys’ Day

Tiefenbacher Group invited some of our employees' children in Hamburg to spend a day with us at our headquarters to mark Germany's Future Day for young people.

The Girls’ & Boys’ Day or Future Day is a good opportunity not only to familiarize young people with the various career paths. It is also a perfect occasion to discuss gender stereotypes in the business world, role models, different life plans, and equality at the workplace.  Straightaway the boys and girls were divided between the various departments IT, Sales, Project Management, Business Development, and the canteen. Not only did they gain a better understanding of the departments’ areas of responsibility, but they were also able to realize their own ideas in small projects. Finally, the results of these projects have enabled our company to offer a different perspective on the needs of the younger generation in the field of pharmaceuticals.

However, we are delighted to have the opportunity to introduce a young generation of interested and open-minded people to our exciting world of pharmaceuticals. We hope to welcome many enthusiastic girls and boys to our company again next year.

Tiefenbacher Group invites young people to Girls’ & Boys’ Day

TIEFENBACHER PHARMACEUTICALS, a part of Tiefenbacher Group, develops and commercializes genericvalue added, and innovative pharmaceuticals as well as medical devices and e-health solutions worldwide. We provide over 180+ pharmaceutical products across various therapeutic categories in 10+ dosage forms. With our in-house product development and manufacturing, we can address specific therapeutic needs in unique formulations of prescription drugs (Rx) and over-the-counter (OTC) medicines for global markets (including highly potent drugs).
For more information about our finished dosage (FDF) forms and healthcare solutions, please contact Tiefenbacher Pharmaceuticals: info@tiefenbacher.com or visit us on: www.tiefenbacher-pharmaceuticals.com

About Tiefenbacher Group – Pioneering Healthcare since 1963

Tiefenbacher Group is a purpose-driven and 100% family-owned healthcare company providing best-in-class solutions along the entire pharmaceutical value chain. From the initial idea to market access of high-quality medicines around the world: We distribute APIs and develop, produce, and register finished dosage forms (FDF) including highly potent drugs as well as medical devices and e-health-solutions. Our purpose is to improve people’s lives by making pharmaceuticals more affordable, more available, and better than ever before.

For further information about our solutions for better healthcare and our in-house capabilities to develop and commercialize pharmaceutical products (including highly potent drugs) and e-health-solutions for global markets, please contact us by email at info@tiefenbacher.com or visit us on www.tiefenbachergroup.com


Tiefenbacher Group Earth Day

Tiefenbacher Group celebrates Earth Day 2024

We are pleased to inform you that TIEFENBACHER GROUP is successfully on its way to becoming climate neutral by the end of 2025*.

Every year, Earth Day provides the keynote for a wide range of campaigns on the broad spectrum of environmental and climate protection for everyone to initiate and permanently implement their personal environmental agenda.

As a value-driven healthcare company, dedicated to improving the life of patients worldwide. We certainly recognise the importance of taking action to tackle the urgent climate crisis we face today. To achieve this goal, we are implementing a comprehensive sustainability strategy, which includes reducing our carbon footprint by cutting energy consumption through energy savings and efficiency measures.  This is correspondingly supported by the installation of large solar panels at our production sites and the use of exclusively electric company vehicles. With these measures, we already achieved a great interim goal of reducing our emissions by 80% by January this year.

Furthermore, we also have our direct impact on our environment in mind and therefore replanted trees and added further vegetation in the course of the conversion work on our properties in order to avoid further harming nature. In addition, we also filter microplastics using a reverse osmosis drinking water facility, so that not only is clean water provided for our schoolchildren in India, but we also minimise ecological disruption at the same time.

We believe that this is not only the right thing to do for the planet but also the right thing to do for our business. Being commercially successful and operating responsibly by becoming climate neutral is how we generate sustainable returns. We look forward to sharing more updates on our progress towards this important goal in the near future.

*Scope 1 and 2 according to GHG as well as business travel and employee commuting

About Tiefenbacher Group – Pioneering Healthcare since 1963

Tiefenbacher Group is a purpose-driven and 100% family-owned healthcare company providing best-in-class solutions along the entire pharmaceutical value chain. From the initial idea to market access of high-quality medicines around the world: We distribute APIs and develop, produce, and register finished dosage forms (FDF) including highly potent drugs as well as medical devices and e-health-solutions. Our purpose is to improve people’s lives by making pharmaceuticals more affordable, more available, and better than ever before.

For further information about our solutions for better healthcare and our in-house capabilities to develop and commercialize pharmaceutical products (including highly potent drugs) and e-health-solutions for global markets, please contact us by email at info@tiefenbacher.com or visit us on www.tiefenbachergroup.com

TIEFENBACHER PHARMACEUTICALS, a part of Tiefenbacher Group, develops and commercializes genericvalue added, and innovative pharmaceuticals as well as medical devices and e-health solutions worldwide. We provide over 180+ pharmaceutical products across various therapeutic categories in 10+ dosage forms. With our in-house product development and manufacturing, we can address specific therapeutic needs in unique formulations of prescription drugs (Rx) and over-the-counter (OTC) medicines for global markets (including highly potent drugs).
For more information about our finished dosage (FDF) forms and healthcare solutions, please contact Tiefenbacher Pharmaceuticals: info@tiefenbacher.com or visit us on: www.tiefenbacher-pharmaceuticals.com


Tiefenbacher first-to-market launch: Rivaroxaban across Europe

Tiefenbacher first-to-market launch: Rivaroxaban

Tiefenbacher Pharmaceuticals successfully prepares the launch of the anticoagulant Rivaroxaban.

We at Tiefenbacher Pharmaceuticals strongly believe that our high-quality medicines should be affordable and available for all patients around the world – irrespective of their nationality or income. That´s why we are thrilled to share that we have successfully prepared a day one launch of the generic version of Rivaroxaban.

Generics are therapeutically equivalent to their branded counterparts with a lower price due to losing patent protection. The low cost of generic medications promotes patient affordability and contributes to lower per capita healthcare spending.

Rivaroxaban is an anticoagulant medication (blood thinner) used to treat and prevent blood clots. It makes blood flow through veins more easily by stopping a clotting factor called factor Xa from working. Rivaroxaban is also used to reduces the risk of stroke and systemic embolism with nonvalvular atrial fibrillation. The tablets are marketed by our cooperation partner, one of the biggest generic pharmaceutical companies in the world. The new generic offers a more affordable alternative for the treatment of blood clotting making it easier for patients to access the treatment they need.

The product has been developed in TIEFENBACHER GROUP´s own laboratories in Hyderabad, India. It has already been launched in several European and international markets before. Furthermore, the successful launch of this anticoagulant reflects our ongoing commitment to providing patients with high-quality, cost-effective medications. Undeniably it is a testament to the hard work and dedication of the team.

Finally, we are particularly excited about the positive impact this achievement will have. However we look forward to further market entries with high-quality medicines – with a patient-centred approach for better healthcare.

Tiefenbacher first-to-market launch: Rivaroxaban across Europe

TIEFENBACHER PHARMACEUTICALS, a part of Tiefenbacher Group, develops and commercializes genericvalue added, and innovative pharmaceuticals as well as medical devices and e-health solutions worldwide. We provide over 180+ pharmaceutical products across various therapeutic categories in 10+ dosage forms. With our in-house product development and manufacturing, we can address specific therapeutic needs in unique formulations of prescription drugs (Rx) and over-the-counter (OTC) medicines for global markets (including highly potent drugs).
For more information about our finished dosage (FDF) forms and healthcare solutions, please contact Tiefenbacher Pharmaceuticals: info@tiefenbacher.com or visit us on: www.tiefenbacher-pharmaceuticals.com

About Tiefenbacher Group – Pioneering Healthcare since 1963

Tiefenbacher Group is a purpose-driven and 100% family-owned healthcare company providing best-in-class solutions along the entire pharmaceutical value chain. From the initial idea to market access of high-quality medicines around the world: We distribute APIs and develop, produce, and register finished dosage forms (FDF) including highly potent drugs as well as medical devices and e-health-solutions. Our purpose is to improve people’s lives by making pharmaceuticals more affordable, more available, and better than ever before.

For further information about our solutions for better healthcare and our in-house capabilities to develop and commercialize pharmaceutical products (including highly potent drugs) and e-health-solutions for global markets, please contact us by email at info@tiefenbacher.com or visit us on www.tiefenbachergroup.com


Tiefenbacher Group welcomes new COO Sandip Tarate

Tiefenbacher Group welcomes new COO Sandip Tarate

We are pleased to welcome our new COO for AET Laboratories, Sandip Tarate, to Tiefenbacher Group.

Sandip has joined our site in Hyderabad, India, with 23+ years of extensive experience in the pharmaceutical sector. To induct and orient Sandip to Tiefenbacher family, our Managing Director Kristian Ruepp has visited our plant in Hyderabad to ensure a great employee on-boarding experience.

In view of Sandip’s first day, Kristian has hosted an inspiring town hall meeting underscoring the importance of the value system in our organization. We are energized about the path ahead for AET Laboratories, our customers, and our partners.

This is currently an exciting phase in our growth journey. The photo of the management team with our colleagues from the construction site extension (in front of the newly built High Potent block) is proof that resilience and teamwork can work wonders!

The completion of the new building is the first step for Tiefenbacher Group to become a leading global developer and manufacturer of highly potent drugs for the treatment of cancer and other diseases. It follows our company´s strategy to make medicines more affordable, more available, and better than before.

Tiefenbacher Group welcomes new COO Sandip Tarate

TIEFENBACHER PHARMACEUTICALS, a part of Tiefenbacher Group, develops and commercializes genericvalue added, and innovative pharmaceuticals as well as medical devices and e-health solutions worldwide. We provide over 180+ pharmaceutical products across various therapeutic categories in 10+ dosage forms. With our in-house product development and manufacturing, we can address specific therapeutic needs in unique formulations of prescription drugs (Rx) and over-the-counter (OTC) medicines for global markets (including highly potent drugs).
For more information about our finished dosage (FDF) forms and healthcare solutions, please contact Tiefenbacher Pharmaceuticals: info@tiefenbacher.com or visit us on: www.tiefenbacher-pharmaceuticals.com

About Tiefenbacher Group – Pioneering Healthcare since 1963

Tiefenbacher Group is a purpose-driven and 100% family-owned healthcare company providing best-in-class solutions along the entire pharmaceutical value chain. From the initial idea to market access of high-quality medicines around the world: We distribute APIs and develop, produce, and register finished dosage forms (FDF) including highly potent drugs as well as medical devices and e-health-solutions. Our purpose is to improve people’s lives by making pharmaceuticals more affordable, more available, and better than ever before.

For further information about our solutions for better healthcare and our in-house capabilities to develop and commercialize pharmaceutical products (including highly potent drugs) and e-health-solutions for global markets, please contact us by email at info@tiefenbacher.com or visit us on www.tiefenbachergroup.com